Market growth is driven by the global prevalence of infectious diseases & onset of COVID-19 and the growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized POC testing and rising technological advancements.

[263 Pages Report] The global infectious disease diagnostics market size is projected to reach USD 39.8 billion by 2026 from USD 28.1 billion in 2021, at a CAGR of 7.2%.

This study involved four major activities in estimating the current size of the infectious disease diagnostics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.

Market Dynamics

• Global prevalence of infectious diseases and onset of COVID-19
• Rising focus on R&D and funding in infectious disease diagnostics
• Growing awareness for early disease diagnosis in developing countries
• Rising technological advancements in infectious disease diagnostics
• Shift in focus from centralized laboratories to decentralized POC testing

COVID-19 Impact on Global Infectious Disease Diagnostics Market

COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (CHINA) in December 2019, COVID-19 moved from a regional crisis to a global pandemic in just a matter of a few weeks. The COVID-19 pandemic negatively affected the overall sales of most of the companies but had an positive impact on the infectious disease diagnostics market because of the use of infectious disease diagnostic methods for COVID-19 testing. Lockdowns resulting from the COVID-19 pandemic caused people to delay undergoing health checkups, thus affecting the number of tests being performed and sales of reagents.

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589

Based on product & service, the infectious disease diagnostics market is segmented into reagents, kits, and consumables; instruments; and software & services. In 2020, the reagents, kits, and consumables segment accounted for the largest share of this market. The frequent purchase of these products due to their recurrent usage drives the market growth of this segment.

The infectious disease diagnostics market is segmented into immunodiagnostics, polymerase chain reaction (PCR), clinical microbiology, isothermal nucleic acid amplification technology (INAAT), DNA sequencing & NGS, DNA microarrays, and other technologies. In 2020, the immunodiagnostics segment accounted for the largest share. This can be attributed to the increasing use of immunoassays in COVID-19 testing, POC infectious disease testing, the development of novel immunodiagnostic tests, and the rising trend of automation.

The geographical regions mapped in the report are:1. North America2. Europe3. Asia-Pacific4. Latin America5. Middle East & Africa

The global infectious disease diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the global infectious disease diagnostics market. The North American infectious disease diagnostics market’s growth can be attributed to the highly developed healthcare system in the US and Canada, the presence of many leading national clinical laboratories, and the easy accessibility to technologically advanced instruments.

Request for sample pages @  https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589

Some key players mentioned in the research report are:

• Abbott Laboratories (US)
• Roche Diagnostics Ltd. (Switzerland)
• bioMérieux SA (France)
• Thermo Fisher Scientific Inc. (US)
• Danaher Corporation (US)

  Market growth is driven by the global prevalence of infectious diseases & onset of COVID-19 and the growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized POC testing and rising technological advancements.

  [263 Pages Report] The global infectious disease diagnostics market size is projected to reach USD 39.8 billion by 2026 from USD 28.1 billion in 2021, at a CAGR of 7.2%.

  This study involved four major activities in estimating the current size of the infectious disease diagnostics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.

  Market Dynamics

  • Global prevalence of infectious diseases and onset of COVID-19
  • Rising focus on R&D and funding in infectious disease diagnostics
  • Growing awareness for early disease diagnosis in developing countries
  • Rising technological advancements in infectious disease diagnostics
  • Shift in focus from centralized laboratories to decentralized POC testing

  COVID-19 Impact on Global Infectious Disease Diagnostics Market

  COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (CHINA) in December 2019, COVID-19 moved from a regional crisis to a global pandemic in just a matter of a few weeks. The COVID-19 pandemic negatively affected the overall sales of most of the companies but had an positive impact on the infectious disease diagnostics market because of the use of infectious disease diagnostic methods for COVID-19 testing. Lockdowns resulting from the COVID-19 pandemic caused people to delay undergoing health checkups, thus affecting the number of tests being performed and sales of reagents.

  Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589

  Based on product & service, the infectious disease diagnostics market is segmented into reagents, kits, and consumables; instruments; and software & services. In 2020, the reagents, kits, and consumables segment accounted for the largest share of this market. The frequent purchase of these products due to their recurrent usage drives the market growth of this segment.

  The infectious disease diagnostics market is segmented into immunodiagnostics, polymerase chain reaction (PCR), clinical microbiology, isothermal nucleic acid amplification technology (INAAT), DNA sequencing & NGS, DNA microarrays, and other technologies. In 2020, the immunodiagnostics segment accounted for the largest share. This can be attributed to the increasing use of immunoassays in COVID-19 testing, POC infectious disease testing, the development of novel immunodiagnostic tests, and the rising trend of automation.

  The geographical regions mapped in the report are:1. North America2. Europe3. Asia-Pacific4. Latin America5. Middle East & Africa

  The global infectious disease diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the global infectious disease diagnostics market. The North American infectious disease diagnostics market’s growth can be attributed to the highly developed healthcare system in the US and Canada, the presence of many leading national clinical laboratories, and the easy accessibility to technologically advanced instruments.

  Request for sample pages @  https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589

  Some key players mentioned in the research report are:

  • Abbott Laboratories (US)
  • Roche Diagnostics Ltd. (Switzerland)
  • bioMérieux SA (France)
  • Thermo Fisher Scientific Inc. (US)
  • Danaher Corporation (US)

Market growth is driven by the global prevalence of infectious diseases & onset of COVID-19 and the growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized POC testing and rising technological advancements.

[263 Pages Report] The global infectious disease diagnostics market size is projected to reach USD 39.8 billion by 2026 from USD 28.1 billion in 2021, at a CAGR of 7.2%.

This study involved four major activities in estimating the current size of the infectious disease diagnostics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.

Market Dynamics

• Global prevalence of infectious diseases and onset of COVID-19
• Rising focus on R&D and funding in infectious disease diagnostics
• Growing awareness for early disease diagnosis in developing countries
• Rising technological advancements in infectious disease diagnostics
• Shift in focus from centralized laboratories to decentralized POC testing

COVID-19 Impact on Global Infectious Disease Diagnostics Market

COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (CHINA) in December 2019, COVID-19 moved from a regional crisis to a global pandemic in just a matter of a few weeks. The COVID-19 pandemic negatively affected the overall sales of most of the companies but had an positive impact on the infectious disease diagnostics market because of the use of infectious disease diagnostic methods for COVID-19 testing. Lockdowns resulting from the COVID-19 pandemic caused people to delay undergoing health checkups, thus affecting the number of tests being performed and sales of reagents.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589

Based on product & service, the infectious disease diagnostics market is segmented into reagents, kits, and consumables; instruments; and software & services. In 2020, the reagents, kits, and consumables segment accounted for the largest share of this market. The frequent purchase of these products due to their recurrent usage drives the market growth of this segment.

The infectious disease diagnostics market is segmented into immunodiagnostics, polymerase chain reaction (PCR), clinical microbiology, isothermal nucleic acid amplification technology (INAAT), DNA sequencing & NGS, DNA microarrays, and other technologies. In 2020, the immunodiagnostics segment accounted for the largest share. This can be attributed to the increasing use of immunoassays in COVID-19 testing, POC infectious disease testing, the development of novel immunodiagnostic tests, and the rising trend of automation.

The geographical regions mapped in the report are:1. North America2. Europe3. Asia-Pacific4. Latin America5. Middle East & Africa

The global infectious disease diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the global infectious disease diagnostics market. The North American infectious disease diagnostics market’s growth can be attributed to the highly developed healthcare system in the US and Canada, the presence of many leading national clinical laboratories, and the easy accessibility to technologically advanced instruments.

Request for sample pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589

Some key players mentioned in the research report are:

• Abbott Laboratories (US)
• Roche Diagnostics Ltd. (Switzerland)
• bioMérieux SA (France)
• Thermo Fisher Scientific Inc. (US)
• Danaher Corporation (US)

What This Report Will Provide?

HPV diagnostics market also formed one of the major market segment in infectious disease diagnostics market. HPV infections can be prevented, if diagnosed in the early stages. Pap tests are the most preferred tests to detect cervical cancer. Rapid HPV diagnostics and real-time PCR are the most advanced methods which have 95% sensitivity to HPV and cover a broad range of

Revenue Growth:

[170 Pages Report]The global infectious disease diagnostics market was valued at USD 13.93 Billion in 2016 and projected to reach USD 19.35 Billion in 2022, at a CAGR of 5.6%.

Major Growth Boosters:

Growth in this market is primarily driven by the increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics.

Download PDF Brochure:   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589 

Growth in the influenza market can be attributed to the rising prevalence of influenza, growth in research funding for influenza diagnostics, and rising demand for faster diagnosis and control of influenza. Advancements in technologies such as PCR and proteomics and significant growth prospects in developing countries are also expected to offer growth opportunities for players in the influenza diagnostics market

Critical questions the report answers:

• Where will all these developments take the industry in the long term?
• What are the upcoming trends for the infectious disease diagnostics market?
• Which segment provides the most opportunity for growth?
• Who are the leading vendors operating in this market?
• What are the opportunities for new market entrants?

Request Sample Report:   https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589 

By product and service, assays, kits and reagents segment to record the highest CAGR during the forecast period

Increased accessibility and the increasing number of IDD tests conducted are the key drivers for this segment. Globally, the volume of IDD tests is increasing mainly due to the rising geriatric population; increasing prevalence of infectious diseases; increased variety of reagents available and analytical techniques employed; and the continuous launch of newer, faster, and more reliable products.

Regional Growth Analysis:

The global healthcare consulting services market was dominated by North America, followed by Europe in 2017. Factors such as increasing M&A activity, pricing pressure on pharmaceutical companies are driving the growth of the healthcare consulting services market in this region. Asia Pacific, however, is estimated to register the highest CAGR during the forecast period due to the increasing need for remote care and telemedicine in rural areas in the region.

Growth in this market is primarily driven by the increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics.

What the Market Looks Like?

The global infectious disease diagnostics market infectious disease diagnostics market was valued at USD 13.93 Billion in 2016 and projected to reach USD 19.35 Billion in 2022, at a CAGR of 5.6%. 

The base year considered for the study is 2016, and the forecast for the market size is provided for the period between 2017 and 2022.

Increased accessibility and the increasing number of IDD tests conducted are the key drivers for this segment. Globally, the volume of IDD tests is increasing mainly due to the rising geriatric population; increasing prevalence of infectious diseases; increased variety of reagents available and analytical techniques employed; and the continuous launch of newer, faster, and more reliable products. 

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589 

By technology, DNA sequencing & next-generation sequencing (NGS) segment to record the highest CAGR during the forecast period

Factors such as advancements in sequencing technologies, increasing awareness and acceptance of personalized medicine (in which this technology has significant applications), and increasing application of molecular diagnostic technologies in pharmacogenetics and point-of-care testing are expected to boost the growth of this technology in the future.

Critical questions the report answers:

• Where will all these developments take the industry in the long term?
• What are the upcoming trends for the infectious disease diagnostics market?
• Which segment provides the most opportunity for growth?
• Who are the leading vendors operating in this market?
• What are the opportunities for new market entrants?

Hepatitis diagnostics market formed the largest share. Around 70% to 90% of the people in these regions (below 40 years of age) are reportedly suffering from the disease and around 8% to 20% are carriers of this virus. Another factor contributing to the growth of this market is the increasing adoption of advanced technologies for the diagnosis of hepatitis B.

North America to account for the largest market size during the forecast period.

North America accounted for the largest share of the global infectious disease diagnostics market. The large share of this region is mainly attributed to the presence of a highly developed healthcare system, increasing prevalence of infectious diseases, the presence of a large number of leading national clinical laboratories, and easy accessibility to technologically advanced instruments in the region.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Growth in this market is primarily driven by the increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics.

Hepatitis diagnostics market formed the largest share. Around 70% to 90% of the people in these regions (below 40 years of age) are reportedly suffering from the disease and around 8% to 20% are carriers of this virus. Another factor contributing to the growth of this market is the increasing adoption of advanced technologies for the diagnosis of hepatitis B.

According to the new market research report by MarketsandMarkets, The global infectious disease diagnostics market was valued at USD 13.93 Billion in 2016 and projected to reach USD 19.35 Billion in 2022, at a CAGR of 5.6%.

Download PDF Brochure:  www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589 

Increased accessibility and the increasing number of IDD tests conducted are the key drivers for this segment. Globally, the volume of IDD tests is increasing mainly due to the rising geriatric population; increasing prevalence of infectious diseases; increased variety of reagents available and analytical techniques employed; and the continuous launch of newer, faster, and more reliable products.

Factors such as advancements in sequencing technologies, increasing awareness and acceptance of personalized medicine (in which this technology has significant applications), and increasing application of molecular diagnostic technologies in pharmacogenetics and point-of-care testing are expected to boost the growth of this technology in the future.

On the basis of disease type, the infectious disease diagnostics (IDD) market is segmented into a wide range of diseases. Hospital acquired infections (HAI) segment to record the highest CAGR during the forecast period. Growth in HAI segment can be attributed to the rising burden of MRSA infections, the increasing number of new products launched in the market, and increasing adoption of technologically advanced HAI diagnostic tests such as BD MAX Cdiff assay, Xpert MRSA NxG, and ARIES C. difficile Assay that are based on PCR technology

North America to account for the largest market size during the forecast period.

North America accounted for the largest share of the global infectious disease diagnostics market. The large share of this region is mainly attributed to the presence of a highly developed healthcare system, increasing prevalence of infectious diseases, the presence of a large number of leading national clinical laboratories, and easy accessibility to technologically advanced instruments in the region.

Request for Sample Pages: www.marketsandmarkets.com/requestsampleNew.asp?id=116764589 

Key Market Players : 

Abbott Laboratories, Becton, Dickinson and Company, Biomérieux SA, Bio-Rad Laboratories, Danaher Corporation, Diasorin, Luminex, Meridian Bioscience, Quidel, Roche Diagnostics, Siemens AG, Thermo Fisher Scientific